Applying molecular measurable residual disease testing in acute myeloid leukaemia.
FLT3
Measurable residual disease
NPM1
acute myeloid leukaemia
clonal haematopoiesis
Journal
Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
29
09
2022
revised:
12
11
2022
accepted:
14
11
2022
pubmed:
13
12
2022
medline:
11
1
2023
entrez:
12
12
2022
Statut:
ppublish
Résumé
Molecular testing in acute myeloid leukaemia (AML) has continued to dramatically advance in recent years, facilitating the ability to detect residual disease at exponentially lower levels. With the advent of the recently updated ELN consensus recommendations, there is increasing complexity to ordering and interpreting measurable residual disease (MRD) assays in AML. We outline the technology itself in conjunction with the relevant testing timepoints, clinically significant thresholds and potential prognostic and therapeutic significance of MRD testing for the major molecular targets in AML. This practical overview should assist haematologists in incorporating molecular MRD assays routinely into their personalised AML clinical management.
Identifiants
pubmed: 36503638
pii: S0031-3025(22)00312-9
doi: 10.1016/j.pathol.2022.11.003
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-7Informations de copyright
Copyright © 2022 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.